Related Experiment Video
Updated: Jan 23, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target.
Su Jin Lee1,2, Sun-Ju Byeon3, Jeeyun Lee1
1Department of Medicine, Division of Hematology-Oncology.
Lymphocyte activation gene 3 (LAG3) was expressed in 18.5% of advanced cancers, notably pancreatic and gastric. Further clinical research into LAG3 as an immunotherapy target is warranted.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Lymphocyte-activation gene 3 (LAG3) is an emerging immune checkpoint inhibitor.
- Understanding LAG3 expression patterns across diverse advanced cancers is crucial for developing novel immunotherapies.
Purpose of the Study:
- To prospectively analyze the expression of LAG3 in a cohort of patients with advanced gastrointestinal, genitourinary, and rare cancers.
- To investigate the correlation of LAG3 expression with clinical and molecular characteristics in metastatic colorectal and gastric cancers.
Main Methods:
- Prospective immunohistochemical analysis of LAG3 expression in 430 patients with advanced cancers.
- Evaluation of LAG3 expression in relation to clinicopathological factors and molecular markers (KRAS, NRAS, BRAF, MSI, EBV) in specific cancer types.
Main Results:
- LAG3 was expressed in 18.5% of evaluated advanced cancers.
- Highest LAG3 expression observed in pancreatic (33.3%) and gastric (24.7%) cancers.
- In metastatic gastric cancer, LAG3 expression was significantly associated with Epstein-Barr virus (EBV) status (P=0.042).
- No significant associations found between LAG3 status and clinicopathological or molecular features in metastatic colorectal cancer.
Conclusions:
- LAG3 is expressed across a spectrum of advanced cancers, with notable prevalence in pancreatic and gastric malignancies.
- The association with EBV status in gastric cancer suggests potential context-specific roles for LAG3.
- These findings support further clinical investigation of LAG3 as a therapeutic target in immunotherapy for various advanced cancers.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
Related Concept Videos
Tumor Immunotherapy
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Molecular Comparison of Gases, Liquids, and Solids